الفهرس 
Non-Alcoholic Fatty Liver Disease OverviewOnly 14 pages are availabe for public view
 |  | from | 79 |  |  |
| | | from | 79 | | |
Abstract
NAFLD is recognized as a leading cause of liver diseases wide world. It ranges from simple steatosis without fibrosis to non-alcoholic steatohepatitis (NASH) with varying stages of fibrosis and NASH-related cirrhosis.
Liver biopsy is the gold standard means to evaluate fibrosis in NAFLD. However, it cannot be used as a routine screening tool to detect or monitor fibrosis progression in NAFLD due to its invasive nature and its rare potential risks of death and sampling variability.
aLiver biopsy samples were taken from each patient after informed consent and then staged according to the biopsy findings. Calculation of the non-invasive scoring systems were done for each patient and compared to the biopsy stage.
After comparing the noninvasive fibrosis scores with the results of liver biopsy, 36 patients out of 40 (according to NFS) and all patients (according to FIB-4 and BARD score) were correlated with the results of liver biopsy.